KEYNOTE-590: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer
JOURNAL FOR IMMUNOTHERAPY OF CANCER（2017）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined